AOD-9604

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from amino acids 176–191 of human growth hormone (HGH). This specific segment of the HGH molecule was identified as the region responsible for lipolytic (fat-mobilizing) activity, while lacking the structural domains responsible for systemic growth promotion.

The foundational characterization of this fragment’s metabolic selectivity is described in:

https://pubmed.ncbi.nlm.nih.gov/11146367/
https://pubmed.ncbi.nlm.nih.gov/11713213/

These studies demonstrated that the 176–191 fragment retains fat-metabolic activity without reproducing the classical anabolic or diabetogenic effects of full-length HGH.

Simply Put

Researchers isolated the small portion of growth hormone that influences fat cells — and removed the parts that cause overall body growth.

Mechanism of Action — Adipose Tissue Effects

1. Lipolysis (Breakdown of Stored Fat)

Lipolysis is the biological process in which stored triglycerides inside fat cells are broken down into free fatty acids and glycerol for energy use.

In vivo metabolic research demonstrated that HGH fragment 176–191 increases lipolysis without stimulating body growth

https://pubmed.ncbi.nlm.nih.gov/11673763/

Cellular adipocyte studies further confirmed this lipolytic activity

https://pubmed.ncbi.nlm.nih.gov/11713213/

These findings established that fat metabolism signaling can be separated structurally from growth hormone’s anabolic effects.

Simply Put

It signals fat cells to release stored energy without affecting height, muscle size, or organ growth.

2. Inhibition of Lipogenesis (Reduction of New Fat Formation)

Lipogenesis refers to the conversion of excess nutrients — especially carbohydrates — into stored fat.

Experimental research demonstrated that HGH 176–191 suppresses lipogenic activity in adipose tissue

https://pubmed.ncbi.nlm.nih.gov/15134286/

This dual mechanism — stimulating fat breakdown while inhibiting new fat storage — is central to the metabolic interest in AOD-9604.

Simply Put

It may help reduce how much new fat the body creates.

Absence of Growth-Promoting and Diabetogenic Effects

Full-length growth hormone can stimulate:

• Linear growth
• Organ enlargement
• Elevation of IGF-1
• Reduced insulin sensitivity in some contexts

However, research demonstrated that the 176–191 fragment does not replicate these endocrine effects

https://pubmed.ncbi.nlm.nih.gov/11146367/

This distinction is critical to understanding why the fragment was investigated separately from full HGH.

Definitions

IGF-1 (Insulin-like Growth Factor 1) – A hormone produced downstream of HGH that mediates tissue growth.

Diabetogenic effect – A biological effect that impairs glucose control or promotes insulin resistance.

Simply Put

Unlike full growth hormone, this fragment did not trigger growth or disrupt blood sugar regulation in research models.

Clinical Development Overview

AOD-9604, developed as a stabilized analogue of HGH 176–191, progressed into formal drug development as an investigational anti-obesity compound.

A comprehensive review of its development history and early clinical findings is described here:

https://pubmed.ncbi.nlm.nih.gov/16625817/

This publication summarizes:

• Preclinical metabolic findings
• Early human safety trials
• Clinical evaluation in overweight populations
• Favorable tolerability profile
• Lack of growth-hormone–mediated side effects

While it did not ultimately achieve commercial drug approval, its safety data and selective mechanism remain scientifically relevant.

Simply Put

The fragment was tested in human trials, showed good safety, and demonstrated metabolic activity — but wasn’t strong enough to become a prescription drug.

Analytical Detection & Laboratory Differentiation

Because HGH fragments differ structurally from endogenous full-length growth hormone, analytical validation studies were performed to ensure they can be accurately identified and distinguished.

Advanced detection and differentiation of HGH-derived fragments are described in:

https://pubmed.ncbi.nlm.nih.gov/25208511/

Such analytical validation supports:

• Structural confirmation
• Laboratory detection reliability
• Differentiation from natural HGH

Simply Put

Scientists can accurately detect and distinguish this fragment from natural growth hormone in laboratory testing.

Scientific Summary (Based Strictly on Cited Publications)

From the studies cited above:

• • HGH fragment 176–191 stimulates lipolysis
  • It inhibits lipogenesis
  • It lacks growth-promoting activity
  • It does not demonstrate diabetogenic effects

• It progressed into investigational clinical development
• It can be analytically differentiated from full HGH

No additional claims are made beyond what the cited literature supports.

Additional Scientific Research Information

Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. “Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone.” Hormone Research, 2000. DOI:

https://doi.org/10.1159/000053182

PubMed:

https://pubmed.ncbi.nlm.nih.gov/11146367/

Heffernan MA, Thorburn AW, Fam B, et al. “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.” International Journal of Obesity, 2001. PubMed:

https://pubmed.ncbi.nlm.nih.gov/11673759/

Heffernan M, Summers RJ, Thorburn A, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology, 2001. PubMed:

https://pubmed.ncbi.nlm.nih.gov/11713213/

Wilding JPH. “AOD-9604 Metabolic.” Current Opinion in Investigational Drugs, 2004. PubMed:

https://pubmed.ncbi.nlm.nih.gov/15134286/

Stier H, Vos E, Kenley D. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism, 2013.

https://www.jofem.org/index.php/jofem/article/view/54/54

More MI, Kenley D, Gianello R. “Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health.” Journal of Endocrinology and Metabolism, 2014.

https://www.jofem.org/index.php/jofem/article/view/138/173

Kwon DR, Park GY. “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.” Annals of Clinical and Laboratory Science, 2015. PubMed:

https://pubmed.ncbi.nlm.nih.gov/26275694/

Misra M. “Obesity Pharmacotherapy: Current Perspectives and Future Directions.” Journal of Pharmacology and Pharmacotherapeutics, 2013. PMC:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/

Cox HD, Hughes CM, Eichner D. “Detection and in vitro metabolism of AOD9604.” Drug Testing and Analysis, 2014. PubMed:

https://pubmed.ncbi.nlm.nih.gov/24039232/

Journal of the American Academy of Orthopaedic Surgeons. “Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.” JAAOS, 2025. PMC:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12753158/

FDA Pharmacy Compounding Advisory Committee (PCAC). “AOD-9604 Memorandum.” December 4, 2024.

https://www.fda.gov/media/183674/download

Wikipedia. “AOD9604”.

https://en.wikipedia.org/wiki/AOD9604

Compliance Statement

AOD-9604 is a research peptide intended solely for laboratory and scientific investigation. It is not approved for human consumption. Information provided is for educational purposes only and does not constitute medical advice or therapeutic claims.